Buying Pfizer Stock Today Could Set You Up for Life
Pfizer (NYSE: PFE) traders obtained some very dangerous information when the corporate was compelled to desert its internally developed GLP-1 weight reduction drug in April, 2025. With patent expirations on the horizon, falling even additional behind opponents like Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) in an rising new drug area of interest…